RayKnowChina Research Map
Shortlist0

Not yet recruitingOesophageal squamous cell carcinomaN/A

Registered title, quoted from ClinicalTrials.gov

Safety and Efficacy Study of Pulsed Electric Field (PEF) Therapy in Patients With Advanced or Unresectable Esophageal Squamous Cell Carcinoma

An open trial on oesophageal squamous cell carcinoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteShanghai Chest Hospital上海市胸科医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06756841, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 20 years to Not stated; sex: all

    Registered eligibility fields

  2. Screening period tumor patients ECOG performance status score of 0 or 1.

    Inclusion criterion 3

  3. Neutrophil count (ANC) ≥1500 cells/mm3

    Inclusion criterion 5

    Platelet count ≥100,000 cells/mm3

    Inclusion criterion 6

    Hemoglobin ≥9 g/dL or ≥5.6 mmol/L

    Inclusion criterion 7

    Serum total bilirubin ≤ 1.5 x ULN.

    Inclusion criterion 8

  4. Any active malignant tumor within 5 years before screening.

    Exclusion criterion 9

    Patients with positive HIV test.

    Exclusion criterion 11

  5. Females of childbearing potential must have a negative serum pregnancy test at screening and be willing to undergo additional pregnancy testing during the study.

    Inclusion criterion 9

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06756841, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Aged 20 years or older when signing the informed consent form.
  • Able to provide written informed consent, and understand and follow the study requirements and assessment schedule.
  • Screening period tumor patients ECOG performance status score of 0 or 1.
  • Laboratory test data within 7 days before the planned PEF treatment date during the screening period must meet the following standards.
  • Neutrophil count (ANC) ≥1500 cells/mm3
  • Platelet count ≥100,000 cells/mm3
  • Hemoglobin ≥9 g/dL or ≥5.6 mmol/L
  • Serum total bilirubin ≤ 1.5 x ULN.
  • Females of childbearing potential must have a negative serum pregnancy test at screening and be willing to undergo additional pregnancy testing during the study.

Exclusion Criteria:

  • Subjects with active respiratory tract infection who need antibiotic or antiviral treatment;
  • Patients with locally advanced ESCC whose tumors can be surgically removed by the investigator or can be potentially cured by radical chemoradiotherapy according to the judgment of local investigators.
  • Patients with esophageal lesions that severely invade adjacent organs (esophagus/bronchus or esophagus/aorta) and are assessed as high-risk esophageal leakage/fistula by the investigator.
  • Evidence of complete esophageal obstruction that is not suitable for treatment, and gastroscopy cannot be performed.
  • Patients with a history of esophageal stent implantation for esophageal obstruction;
  • Patients with a history of gastrointestinal bleeding in the past 4 weeks, or gastroscopy indicates a high risk of tumor ulcer bleeding.
  • Patients with obstruction caused by anastomotic stenosis without esophageal primary lesions after previous esophageal cancer surgery.
  • Patients with active leptomeningeal disease or brain metastasis.
  • Any active malignant tumor within 5 years before screening.
  • Subjects have undergone metal implantation surgery such as esophageal stents and airway stents. Or the patient has an implantable cardioverter-defibrillator, pacemaker or other implantable electronic device.
  • Patients with positive HIV test.
  • Subjects are currently participating in other research clinical trials;
  • Subjects who are considered by the investigator to have other high-risk conditions and are not suitable for gastroscopy and surgery;
  • Subjects who have adverse events that have not yet returned to baseline or stable levels due to previous anti-tumor treatment, except for adverse events that do not pose safety risks (such as hair loss and abnormal values of specific laboratory tests)

Quoted from ClinicalTrials.gov, NCT06756841, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06756841, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06756841